Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Neoadjuvant Therapy × Clear all
NCT01458717 2018-05-02

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Seoul National University Hospital

Phase 2/3 Completed
58 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡